MAIA Biotechnology, Inc. cotiza a 1.18 USD y tiene una capitalización bursátil de $73M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCL…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.13 | $-0.14 | $-0.14 | $-0.27 |
| Estimado | $-0.11 | $-0.18 | $-0.13 | $-0.19 |
| Sorpresa | -18.2% | +22.2% | -7.7% | -42.1% |
| Métrica | MAIA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -942.6% | -40.4% | -902.3% |
| ROA | -230.8% | -32.0% | -198.8% |
| Current Ratio | 1.66 | 2.84 | -1.18 |
| Debt / Equity | — | 0.28 | — |